EXEL
EXEL
NASDAQ · Biotechnology

Exelixis Inc

$58.15
+0.93 (+1.63%)
As of Sep 22, 9:43 PM ET ·
Analyst Consensus
Hold
27
Analysts
High
Coverage
Buy 12 44%
Hold 14 52%
Sell 1 4%
Price Target
Analyst Price Target +99.7% upside
Low Target $78.53
Average Target $116.10
High Target $123.77
Current Price $58.15
Current
$58.15
Target
$116.10
$78.53 $116.10 avg $123.77
Scenario Analysis
Bear Case
$78.53
35.0%
Low target
Base Case
$116.10
+99.7%
Avg target
Bull Case
$123.77
+112.8%
High target
Risk/Reward
3.2x
Highly favorable
Price in Context
52-Week High
$59.72
-2.6% from high
52-Week Low
$33.76
+72.2% from low
50-Day SMA
$43.59
+33.4% vs SMA
200-Day SMA
$41.49
+40.2% vs SMA
RSI (14)
62.0
Neutral
Target vs 52W High
$116.10
+94.4% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 39 82% $257.58 -2.9%
AMGN
Amgen Inc
Hold 43 47% $190.87 -53.5%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +137.6%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 36 81% $438.34 -14.9%
REGN
Regeneron Pharmaceuticals
Buy 38 68% $76.80 -90.4%
MRNA
Moderna Inc
Hold 30 37% $149.45 -18.1%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -63.4%
RVMD
Revolution Medicines Inc
Strong Buy 28 93% $114.11 -40.8%